NON-HODGKINS-LYMPHOMA IN THE ELDERLY - A STUDY OF 602 PATIENTS AGED 70 OR OLDER FROM A DANISH POPULATION-BASED REGISTRY

被引:76
作者
DAMORE, F
BRINCKER, H
CHRISTENSEN, BE
THORLING, K
PEDERSEN, M
NIELSEN, JL
SANDBERG, E
PEDERSEN, NT
SORENSEN, E
机构
[1] AARHUS KOMMUNE HOSP,DEPT ONCOL,DK-8000 AARHUS,DENMARK
[2] AALBORG HOSP,DEPT ONCOL,DK-9000 AALBORG,DENMARK
[3] HOLSTEBRO HOSP,DEPT MED,HOLSTEBRO,DENMARK
[4] ESBJERG CENT HOSP,DEPT ONCOL,ESBJERG,DENMARK
[5] ODENSE UNIV HOSP,DEPT PATHOL,DK-5000 ODENSE,DENMARK
[6] AARHUS KOMMUNE HOSP,DEPT MED PHYS,DK-8000 AARHUS,DENMARK
关键词
LYMPHOMA; NON-HODGKINS; ELDERLY; CLINICOPATHOLOGICAL FEATURES; PROGNOSIS;
D O I
10.1093/oxfordjournals.annonc.a058211
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Within a 7-year period 1,597 newly diagnosed cases of non-Hodgkin's lymphoma (NHL) were included in a Danish population-based NHL registry. Of these, 602 (38%) were aged 70 years or older (age range 70-94, median: 76.8). They represent the population defined as 'elderly' patients in the present study. The average annual incidence rate for this elderly patient population was 35.7/10(5), as compared with 6.6/10(5) for patients aged < 70 (overall annual incidence: 9.5/10(5)). Localised cases (stage I and II) and extranodal manifestations were found more frequently among elderly patients. The most common sites of extranodal involvement were the stomach (21% of all extranodal cases) and the bone marrow (16%). Histologically, follicular centroblastic/centrocytic cases were found to be less frequent (p < 0.01) in elderly patients as compared to their younger counterparts (< 70 years), who in contrast had a lower occurrence of diffuse centroblastic cases (p < 0.01). Overall 7-year survival for the elderly patient population was 35% (median 1.7 years), and for patients aged < 70 it was 57%. This difference persisted after correction for apparently NHL-unrelated deaths (52% vs. 66%, respectively, p < 0.0001). Elderly patients with poor prognosis were characterised by the following features identified in a Cox-regression model: hepatic involvement, presence of B-symptoms, high-grade histology and elevated s-LDH. The corresponding relative risk values were in the order 2.4, 2.2, 1.9 and 1.6.
引用
收藏
页码:379 / 386
页数:8
相关论文
共 29 条
[1]   PHASE-III TRIAL OF CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) VERSUS CISPLATIN, ETOPOSIDE, BLEOMYCIN AND PREDNISONE (CISEBP) FOR THE TREATMENT OF ADVANCED NON-HODGKINS-LYMPHOMA OF HIGH-GRADE MALIGNANCY [J].
ANDERSEN, J ;
THORLING, K ;
BENTZEN, SM ;
BRINCKER, H ;
CHRISTENSEN, BE ;
PEDERSEN, M .
ACTA ONCOLOGICA, 1990, 29 (08) :995-999
[2]  
ANDERSON T, 1982, CANCER, V50, P2693
[3]  
[Anonymous], 1982, CANCER, V49, P2112
[4]  
CARBONE A, 1986, CANCER, V57, P2185, DOI 10.1002/1097-0142(19860601)57:11<2185::AID-CNCR2820571117>3.0.CO
[5]  
2-N
[6]   AGE-RELATED-CHANGES IN THE MORPHOLOGY AND IMMUNOPHENOTYPE OF SPONTANEOUS LYMPHOMAS OF SJL/N MICE [J].
CHOW, EYW ;
HO, FCS .
JOURNAL OF PATHOLOGY, 1988, 156 (04) :331-339
[7]  
COX DR, 1972, J R STAT SOC B, V34, P187
[8]   CLINICOPATHOLOGICAL FEATURES AND PROGNOSTIC FACTORS IN EXTRANODAL NON-HODGKIN LYMPHOMAS [J].
DAMORE, F ;
CHRISTENSEN, BE ;
BRINCKER, H ;
PEDERSEN, NT ;
THORLING, K ;
HASTRUP, J ;
PEDERSEN, M ;
JENSEN, MK ;
JOHANSEN, P ;
ANDERSEN, E ;
BACH, B ;
SORENSEN, E .
EUROPEAN JOURNAL OF CANCER, 1991, 27 (10) :1201-1208
[9]  
ELIAS L, 1979, CANCER, V43, P2540, DOI 10.1002/1097-0142(197906)43:6<2540::AID-CNCR2820430655>3.0.CO
[10]  
2-D